SIGHT FOR LIFE

Transforming lives by developing innovative treatment for ocular disease that helps restore sight for life

SIGHT FOR LIFE

Transforming lives by developing innovative treatment for ocular disease that helps restore sight for life

For the future of every childs vision.

ABOUT

Theialife is a virtual late-clinical stage novel ophthalmology drug company founded on an unyielding commitment to develop innovative breakthrough drug therapies for ophthalmological applications that have unmatched potential to advance the existing standard of care to prevent sight deterioration, restore patient vision and enrich lives.

NOVEL PIPELINE

We have a portfolio of first-in-class molecules that address large-unmet vision-threatening retinal diseases that can lead to further complications, like retinal detachment or blindness.

MYOPIA, THE SILENT EPIDEMIC

Our lead asset, ND10 is poised to become the first oral therapy for early-onset-paediatric myopia and is set to enter global Phase III clinical trials in 2025.
20 years of real-world clinical usage in Denmark, with nil reported adverse effects.

IMPACT WITH NUMBERS

Theialife’s commitment to innovation is reflected in our impressive metrics, demonstrating our impact in ophthalmology

2.2 B

People with vision impairement

2.64 B

People who have myopia

460 M

People with high myopia

Meet us at

Theialife article is published in the British Journal of Ophthalmology

Theialife is featured on the front cover of the coveted British Journal of Ophthalmology To learn more about the groundbreaking benefits of 7-Methyl-Xanthine in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.
August 22, 2022
Read more

Theialife is featured in the International Journal of Ophthalmology

Theialife article is published in the International Journal of Ophthalmology Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”
January 31, 2023 
Read more